In particular, dysregulation of Cdk12 activity has been associated with several types of human cancers, including breast, ovarian, prostate, and gastric cancer, and has highlighted the importance of Cdk12 as a promising diagnostic biomarker and potential therapeutic target (30, 31). The gene discussed is CDK12; the disease is cancer.